dc.contributor.author | Benson, C | |
dc.contributor.author | Ray-Coquard, I | |
dc.contributor.author | Sleijfer, S | |
dc.contributor.author | Litière, S | |
dc.contributor.author | Blay, J-Y | |
dc.contributor.author | Le Cesne, A | |
dc.contributor.author | Papai, Z | |
dc.contributor.author | Judson, I | |
dc.contributor.author | Schöffski, P | |
dc.contributor.author | Chawla, S | |
dc.contributor.author | Gil, T | |
dc.contributor.author | Piperno-Neumann, S | |
dc.contributor.author | Marréaud, S | |
dc.contributor.author | Dewji, MR | |
dc.contributor.author | van der Graaf, WTA | |
dc.date.accessioned | 2016-12-12T13:42:19Z | |
dc.date.issued | 2016-07 | |
dc.identifier.citation | Gynecologic oncology, 2016, 142 (1), pp. 89 - 94 | |
dc.identifier.issn | 0090-8258 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/324 | |
dc.identifier.eissn | 1095-6859 | |
dc.identifier.doi | 10.1016/j.ygyno.2016.03.024 | |
dc.description.abstract | Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest outcome to systemic therapy, and poor overall survival. Pazopanib is a multi-targeted tyrosine kinase inhibitor approved for non-adipocytic advanced soft tissue sarcomas (STS). Here we investigated whether response to pazopanib in patients with uterine sarcomas differs from that of patients with non-uterine sarcomas.Patients and methods Uterine sarcoma patients were retrieved from all soft tissue sarcoma patients treated with pazopanib in EORTC Phase II (n=10) and Phase III (PALETTE) (n=34) studies. Patient and tumour characteristics, response, progression free and overall survival data were compared.Results Forty-four patients with uterine sarcoma were treated with pazopanib. The majority of patients had uterine leiomyosarcoma (LMS) (n=39, 88.6%) with high grade tumours (n=37, 84.1%) compared to 54.8% (n=164) in the non-uterine population. The median age was 55years (range 33-79) and median follow up was 2.3years. Uterine patients were heavily pre-treated, 61.3% having ≥2 lines of chemotherapy prior to pazopanib compared to 40.8% in the non-uterine population. Five patients (11%), all LMS, had a partial response (95% CI 3.8-24.6). Median progression free survival (PFS) 3.0months (95% CI 2.5-4.7) in uterine versus 4.5 (95% CI 3.7-5.1) in non-uterine STS. Median overall survival (OS) was 17.5months (95% CI 11.1-19.6), longer than the non-uterine population, 11.1months (95% CI 10.2-12.0) (p=0.352).Conclusions Despite heavy pre-treatment, pazopanib shows signs of activity in patients with uterine sarcoma with the similar outcomes to patients with non-uterine STS. | |
dc.format | Print-Electronic | |
dc.format.extent | 89 - 94 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Humans | |
dc.subject | Leiomyosarcoma | |
dc.subject | Sarcoma | |
dc.subject | Uterine Neoplasms | |
dc.subject | Sulfonamides | |
dc.subject | Pyrimidines | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Prognosis | |
dc.subject | Survival Rate | |
dc.subject | Retrospective Studies | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Young Adult | |
dc.title | Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-03-18 | |
rioxxterms.versionofrecord | 10.1016/j.ygyno.2016.03.024 | |
rioxxterms.licenseref.startdate | 2016-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Gynecologic oncology | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.publication-status | Published | |
pubs.volume | 142 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical and Translational Sarcoma | en_US |
icr.researchteam | Sarcoma Clinical Trials | en_US |
dc.contributor.icrauthor | van der Graaf, Wilhelmina | |
dc.contributor.icrauthor | Judson, Ian | |